Investigation on the effect of immune selection on resistance to bactericidal antibodies to group B meningococci in vitro.
The induction of resistance by immune selective pressure to bactericidal antibodies from humans immunized with Novartis recombinant meningococcal group B vaccines was assessed. Serum bactericidal antibody titers against selected bacteria were within assay variability through a selection event frequency of 1 in 10(-5). No change in antigen expression was observed by Western blotting.
Santos
George F
GF
Novartis Vaccines, 350 Mass Ave., Cambridge, MA 02139, USA. george.santos@novartis.com
Giuliani
Marzia
M
Santini
Laura
L
Adu-Bobie
Jeanette
J
Pizza
Mariagrazia
M
Rappuoli
Rino
R
Wacknov
William
W
Donnelly
John
J
D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology*; D001770:Blood Bactericidal Activity; D006801:Humans; D022401:Meningococcal Vaccines / Q000276:immunology*; D050296:Microbial Viability; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D012641:Selection, Genetic
D000907:Antibodies, Bacterial; D022401:Meningococcal Vaccines